Daily Sepsis Research Analysis
Analyzed 32 papers and selected 3 impactful papers.
Summary
Three high-impact studies advance sepsis science across mechanisms, systems biology, and pathogen virulence. A mechanistic paper identifies hepatocyte RXRα as a master regulator of hepatic immunity and metabolic stability in polymicrobial sepsis. A multi-omic cohort defines a host–lung microbiome metasystem that predicts pneumonia, mortality, and interferon-γ treatment heterogeneity, while a pathogen-focused study shows that hvKP Hcp triggers endothelial pyroptosis via an HMGB1–RAGE axis.
Research Themes
- Hepatic immunometabolism and nuclear receptor signaling in sepsis
- Host–microbiome–metabolome integration for risk stratification
- Pathogen virulence mechanisms driving endothelial injury and sepsis severity
Selected Articles
1. RXRα suppression drives hepatic metabolic and immune dysfunction in sepsis.
This mechanistic study shows that hepatocyte RXRα maintains metabolic stability and antibacterial defense during polymicrobial sepsis. Prophylactic, but not therapeutic, bexarotene improved survival in mice, and hepatocyte-specific RXRα loss reduced Kupffer cells, leading to bacterial dissemination and mortality.
Impact: It identifies a nuclear receptor-controlled hepatic program that links hepatocyte transcriptional competence to systemic antibacterial defense, revealing a druggable axis with temporal constraints.
Clinical Implications: Hepatocyte RXRα emerges as a potential target to preserve hepatic immune-metabolic fitness in early sepsis. Timing appears critical; prophylactic/very-early activation may help, whereas later activation may be ineffective, guiding trial design and biomarker-driven patient selection.
Key Findings
- Sepsis rapidly downregulates hepatocyte RXRα at mRNA and protein levels under HNF4α control.
- Prophylactic, but not therapeutic, bexarotene improves survival by preserving metabolic stability and bacterial clearance.
- Hepatocyte-specific RXRα loss depletes Kupffer cells, driving bacterial dissemination and mortality, linking hepatocellular competence to hepatic macrophage niches.
Methodological Strengths
- Combined genetic (hepatocyte-specific inducible RXRα knockout) and pharmacologic perturbations with transcriptomics.
- In vivo survival evaluation and mechanistic linkage to Kupffer cell niche maintenance.
Limitations
- Protective effects observed only with prophylactic bexarotene; septic liver showed partial pharmacologic resistance.
- Preclinical models; human translatability, dosing, and timing remain to be established.
Future Directions: Define optimal timing and ligands for RXRα activation, develop biomarkers of hepatic RXRα activity, and test RXRα-targeted strategies in early-phase, time-sensitive clinical trials.
Sepsis is a life-threatening condition in which a dysregulated host response to infection leads to organ dysfunction and metabolic and immune failure. We identify hepatocyte retinoid X receptor α (RXRα) as a key integrator of host resilience during polymicrobial sepsis. RXRα is transcriptionally regulated by hepatocyte nuclear factor 4α (HNF4α), and sepsis rapidly decreases RXRα mRNA and protein levels. Transcriptomic analyses show that the septic liver becomes partially resistant to pharmacological activation of RXRα with bexarotene.
2. Alterations of the host-lung microbiome metasystem in systemic inflammatory response syndrome is associated with secondary pneumonia.
A longitudinal multi-omic cohort in SIRS defines a host–lung microbiome metasystem state that predicts secondary pneumonia and mortality. Findings were robust in an independent randomized trial, and analyses suggest interferon-γ may benefit patients with severe metasystem alterations but harm those with moderate alterations.
Impact: Introduces a systems-level, biomarker-driven framework for early stratification and treatment selection in critically ill inflammatory states overlapping with sepsis.
Clinical Implications: Metasystem-based stratification could guide surveillance for secondary pneumonia and personalize immunomodulation (e.g., interferon-γ) to avoid harm. Prospective, biomarker-guided trials are warranted.
Key Findings
- Defined a host–lung microbiome metasystem integrating respiratory microbiome, blood metabolome, and immune cell features.
- Identified a metacluster (T/B cell trafficking, anaerobes, high tyrosine metabolism, low fatty acid biosynthesis) predicting pneumonia and mortality.
- Robustness demonstrated in an independent randomized controlled trial; interferon-γ may benefit severe but harm moderate metasystem alterations.
Methodological Strengths
- Longitudinal, multi-omic profiling integrating microbiome, metabolome, and immune phenotyping.
- External validation in an independent randomized controlled trial dataset.
Limitations
- Primary cohort in SIRS rather than strictly culture-proven sepsis; generalizability to all sepsis phenotypes remains to be shown.
- Observational associations; interventional utility of metasystem-guided therapy requires prospective testing.
Future Directions: Develop clinically deployable assays to classify metasystem states and design biomarker-stratified trials testing interferon-γ and other immunomodulators.
Host-respiratory microbiome interplay is vital to lung homeostasis. Systemic inflammatory response syndrome (SIRS) is an intense alteration in host status that necessitates rapid microbiome adaptation to avoid respiratory complications. Using longitudinal multi-omic data from patients with SIRS, we confirm that the respiratory microbiome, blood metabolome, and immune cells form a dynamic metasystem and define a metacluster with distinct T/B cell trafficking, anaerobic bacteria, high tyrosine metabolism, and low fatty acid biosynthesis. This metacluster status can serve to classify the severity of alterations in host-lung microbiome interactions as moderate or severe and to predict pneumonia and mortality.
3. The T6SS Effector Hcp of Hypervirulent Klebsiella pneumoniae Exacerbates Liver Abscess by Inducing Macrophage-HMGB1/RAGE-Dependent Endothelial Pyroptosis.
hvKP Hcp triggers macrophage HMGB1 release; Hcp–HMGB1 complexes enter endothelial cells via RAGE to induce canonical pyroptosis with IL-1β/IL-18 release. Genetic and pharmacologic disruptions (HMGB1 knockout, caspase-1 knockdown, RAGE inhibition) abrogate effects, and hcp-knockout hvKP improves survival and reduces endothelial injury in mice.
Impact: Reveals a discrete hvKP virulence axis (Hcp–HMGB1–RAGE–caspase-1) linking macrophage–endothelial crosstalk to endothelial pyroptosis and outcomes, identifying multiple actionable nodes.
Clinical Implications: Therapeutic strategies disrupting HMGB1 release, RAGE engagement, or downstream inflammasome/caspase-1 activation may mitigate endothelial injury in hvKP sepsis and liver abscess.
Key Findings
- Hcp induces macrophage HMGB1 secretion; Hcp–HMGB1 complexes drive endothelial pyroptosis via RAGE with IL-1β/IL-18 release.
- HMGB1 knockout, caspase-1 knockdown, or RAGE inhibition abolishes endothelial pyroptosis and activation.
- Mice infected with hcp-knockout hvKP exhibit improved survival, lower serum HMGB1, and reduced endothelial injury.
Methodological Strengths
- Use of wild-type, knockout, and complemented bacterial strains with pathway-specific loss-of-function validation.
- Translation across systems: macrophage–endothelial co-culture mechanisms and in vivo survival/vascular injury readouts.
Limitations
- Endothelial studies used HUVECs; tissue-specific endothelial responses in vivo may differ.
- Clinical translation requires validation across hvKP lineages and evaluation of targetability and safety of HMGB1/RAGE modulation.
Future Directions: Assess HMGB1/RAGE inhibitors and caspase-1 modulation in hvKP infection models and develop diagnostics to identify patients with HMGB1–RAGE–driven endothelial injury.
OBJECTIVES: Hypervirulent Klebsiella pneumoniae (hvKP) causes pyogenic liver abscess and fulminant sepsis via vascular endothelial dysfunction and injury. This study aimed to elucidate how its type VI secretion system (T6SS) effector hemolysin-coregulated protein (Hcp) compromises vascular integrity by inducing endothelial pyroptosis. METHODS: We stimulated macrophages with Hcp or hvKP strains (wild-type/ hcp-knockout/ complemented), then applied supernatants to human umbilical vein endothelial cells (HUVECs) to evaluate pyroptosis, cytokine release, and endothelial activation. Mechanistic validation studies employed high-mobility group box 1 (HMGB1)